PAX8 Expression in Uterine Adenocarcinomas and Mesonephric Proliferations

被引:37
|
作者
Yemelyanova, Anna [1 ]
Gown, Allen M. [4 ]
Wu, Lee-Shu-Fune [3 ]
Holmes, Brittany J. [1 ]
Ronnett, Brigitte M. [1 ,2 ]
Vang, Russell [1 ,2 ]
机构
[1] Johns Hopkins Univ Sch Med & Hosp, Div Gynecol Pathol, Dept Pathol, Baltimore, MD USA
[2] Johns Hopkins Univ Sch Med & Hosp, Dept Obstet Gynecol, Baltimore, MD USA
[3] Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[4] PhenoPath Labs, Seattle, WA USA
关键词
PAX8; Immunohistochemistry; Uterus; Adenocarcinoma; Mesonephric proliferations; ENDOMETRIAL CANCER; DIAGNOSTIC UTILITY; EPITHELIAL TUMORS; IN-SITU; CARCINOMA; P53; IMMUNOHISTOCHEMISTRY; DISTINCTION; NEOPLASMS; MARKER;
D O I
10.1097/PGP.0b013e3182a54afa
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
PAX8 is a useful immunohistochemical marker for the diagnosis of gynecologic tract malignancies. Several studies have described PAX8 expression in a wide variety of epithelial neoplasms, including ovarian and endometrial carcinomas. The goal of this study was to evaluate PAX8 expression in various types of uterine adenocarcinomas and mesonephric proliferations. Ninety-four cases of uterine adenocarcinomas (52 endometrial endometrioid carcinomas, 21 endometrial serous carcinomas, and 21 human papillomavirus-related endocervical carcinomas), 11 cases of benign mesonephric proliferations (remnants/hyperplasia), and normal endometrial and endocervical glandular epithelium in 58 cases were studied. Immunohistochemical staining was performed with the rabbit polyclonal anti-PAX8 antibody. All adenocarcinoma groups demonstrated a high frequency of PAX8 expression but with relatively high variability in the extent of staining among different subtypes. Both serous carcinomas and endometrioid carcinomas were positive in most cases (95% and 96%, respectively), but serous carcinomas displayed a significantly higher level of expression (immunohistochemical composite scores based on combined extent and intensity of expression) compared with endometrioid carcinomas (mean immunohistochemical composite scores: 8.3 vs. 5.3, respectively; P<0.006). Endocervical adenocarcinomas also had a high frequency of PAX8 expression (86% of cases), but the level of expression was significantly less than that of endometrial adenocarcinomas (mean immunohistochemical composite scores: 2.9 vs. 5.3-8.3, respectively; P<0.004). Among benign glandular epithelia, normal endocervical glands exhibited a significantly lower level of expression compared with either normal endometrial glands or benign mesonephric proliferations (mean immunohistochemical composite scores: 2.6 vs. 6.6-11.2, respectively; P<0.0006). We conclude that PAX8 is expressed in the vast majority of uterine adenocarcinomas, including those of both endometrial and endocervical origin, and that the level of expression based on combined extent and intensity is highest in endometrial serous carcinoma and lowest in endocervical adenocarcinoma. However, the high prevalence of PAX8 expression in the various types of uterine adenocarcinomas precludes use of this marker for distinguishing these tumors. In extrauterine sites, PAX8 can serve as a useful marker for adenocarcinomas of uterine origin (also positive in the majority of ovarian carcinomas), being most sensitive for identification of endometrial adenocarcinomas (both serous and endometrioid). The sensitivity for identifying metastatic endocervical adenocarcinomas is likely less and dependent on the degree to which the significantly lower extent of expression in these tumors is maintained in metastatic sites.
引用
收藏
页码:492 / 499
页数:8
相关论文
共 50 条
  • [21] PAX8 expression in human bladder cancer
    Pellizzari, Lucia
    Puppin, Cinzia
    Mariuzzi, Laura
    Saro, Francesca
    Pandolfi, Maura
    Di Lauro, Roberto
    Beltrami, Carlo Alberto
    Damante, Giuseppe
    ONCOLOGY REPORTS, 2006, 16 (05) : 1015 - 1020
  • [22] Immunohistochemical expression of PAX8, PAX2, and cytokeratin in melanomas
    Plotzke, Jaclyn M.
    Zhao, Raymond
    Hrycaj, Steven M.
    Harms, Paul W.
    Mehra, Rohit
    Chan, May P.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2021, 48 (10) : 1246 - 1251
  • [23] PAX8 expression in ovarian surface epithelial cells
    Adler, Emily
    Mhawech-Fauceglia, Paulette
    Gayther, Simon A.
    Lawrenson, Kate
    HUMAN PATHOLOGY, 2015, 46 (07) : 948 - 956
  • [24] Significance analysis of PAX8 expression in endometrial carcinoma
    Hu, Shan
    Gan, Hua
    Yang, Fengmei
    MEDICINE, 2022, 101 (42) : E31159
  • [25] PAX8 Expression in Non-Epithelial Neoplasia
    Rottmann, Douglas
    Chan, May
    Thomas, Dafydd
    Patel, Rajiv
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 64 - 66
  • [26] PAX8 Expression in Non-Epithelial Neoplasia
    Rottmann, Douglas
    Chan, May
    Thomas, Dafydd
    Patel, Rajiv
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 64 - 66
  • [27] Evaluation of PAX2 and PAX8 Expression in Salivary Gland Neoplasms
    Butler R.T.
    Alderman M.A.
    Thompson L.D.R.
    McHugh J.B.
    Head and Neck Pathology, 2015, 9 (1) : 47 - 50
  • [28] Diagnostic role of immunostaining for thyroid transcription factor 1 (TTF1) and paired box 8 (PAX8) in distinguishing pulmonary metastases of mesonephric and mesonephric-like adenocarcinomas from primary lung adenocarcinoma
    Kim, H.
    Ji, N.
    Kim, H.
    VIRCHOWS ARCHIV, 2024, 485 : S89 - S90
  • [29] PAX8 expression in the primary peritoneal serous carcinoma
    Seki, K.
    Kushima, R.
    Hayakawa, K.
    Tanno, T.
    HISTOPATHOLOGY, 2012, 61 : 110 - 111
  • [30] PAX8 Expression in Adenocarcinoma of the Retinal Pigment Epithelium
    Hanbazazh, Mehenaz
    Thuro, Bradley
    Gyure, Kymberly
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2017, 76 (06): : 506 - 506